JP Morgan analyst Jessica Fye maintains Halozyme Therapeutics (NASDAQ:HALO) with a Neutral and ra

Halozyme wins a Dutch court order blocking Merck's Keytruda SC in eight European markets, strengthen

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO)

Halozyme expands its ENHANZE pact with argenx to eight targets, opening the door to new milestones a

SAN DIEGO, Oct. 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or th

Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today annou

Expanded agreement increases argenx's exclusive access to ENHANZE® from six to eight targets SAN DIE

Halozyme Therapeutics (NASDAQ:HALO) has outperformed the market over the past 15 years by 8.16% on a

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company"), today annou

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO)

3 health care stocks with high momentum could be overbought. Crinetics Pharmaceuticals (CRNX) has RS

Leerink Partners analyst David Risinger upgrades Halozyme Therapeutics (NASDAQ:HALO) from Market

TD Cowen analyst Brendan Smith maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raise

U.S. stocks rose, Nasdaq Composite up 1%. Natera Inc (NTRA) shares jump 20.5% after strong Q2 result

Citizens analyst Jason N. Butler maintains Halozyme Therapeutics (NASDAQ:HALO) with a Market Outp

Wells Fargo analyst Mohit Bansal maintains Halozyme Therapeutics (NASDAQ:HALO) with a Equal-Weigh

Wall Street analysts changed ratings & price targets for top stocks. Check out all changes inclu

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $2.28 per share which beat the an

Halozyme Therapeutics (NASDAQ:HALO) raises FY2026 Adj EPS guidance from $7.75-$8.25 to $8.65-$9.00 v

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announ

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today confir

Morgan Stanley analyst Vikram Purohit maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overwe

Halozyme Therapeutics (NASDAQ:HALO) affirms FY2026 Adj EPS guidance from $7.75-$8.25 to $7.75-$8.25

Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $1.60 per share which beat the an

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announ

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO)

Tech stocks recovered on Wednesday, led by a rally in battered software names, as the Nasdaq 100 jum

Stocks were rising again midday Friday, putting Wall Street on pace for a fifth straight day of gain

Halozyme stock rises after withdrawing its €2B acquisition offer for Evotec, while reaffirming stron

Halozyme offers to acquire Evotec for €11.00 per share, boosting Evotec's value to €2 billion. T

Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causi

Shares of Biophytis S.A. (NASDAQ: BPTS) rose sharply in today’s pre-market trading after reporting

Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn